Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 3/20 | 0.45 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097800 | 0.91 | PPARA (0.52) | PPARASTING1KDM4CLCKNOX4 | |
| SCHEMBL610930 | 0.86 | PPARA (0.57) | PPARASTING1KDM4CLCKNOX4 | |
| SCHEMBL29391594 | 0.86 | PPARA (0.57) | PPARASTING1KDM4CLCKNOX4 | |
| SCHEMBL608498 | 0.83 | KDM4C (0.53) | PPARASTING1KDM4CLCKNOX4 | |
| SCHEMBL4116154 | 0.81 | KDM4C (0.52) | PPARASTING1KDM4CLCKNOX4 | |
| SCHEMBL28928409 | 0.81 | PPARA (0.52) | PPARASTING1KDM4CLCKNOX4 | |
| SCHEMBL608886 | 0.80 | KDM4C (0.50) | PPARASTING1KDM4CLCKNOX4 | |
| SCHEMBL610123 | 0.80 | SYK (0.58) | PPARASTING1KDM4CLCKNOX4 | |
| SCHEMBL29388077 | 0.80 | SYK (0.58) | PPARASTING1KDM4CLCKNOX4 | |
| SCHEMBL29390970 | 0.80 | CNR1 (0.52) | PPARASTING1KDM4CLCKNOX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-11-29 | — | — | US | disclosed |
| US-20090149542-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2009-06-11 | — | — | US | disclosed |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149542-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | BCL2, BAX, SMN1; SMN2 | PPARA 1265/4885STING1 3945/4885KDM4C 3544/4885 |
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | BCL2, BAX, SMN1; SMN2 | PPARA 1265/4885STING1 3945/4885KDM4C 3544/4885 |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | BCL2, BAX, SMN1; SMN2 | PPARA 1265/4885STING1 3945/4885KDM4C 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.